RxDoctor Payments Data

Mahir Elder, MD

Cardiovascular Disease · Detroit, MINPI 1962427260

Payments from drug & device makers

$110,744in general payments, 2019–2025

Across 1,043 payments — averaging $106.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$48K
  • Angiodynamics, Inc.$18K
  • Pfizer$12K
  • Cardiovascular Systems Inc.$4K
  • Bayer$3K
  • Boston Scientific$3K
  • plus $23K from 54 others

What the payments were for

  • Consulting fees$8,61913%
  • Speaking & faculty fees$14,51821%
  • Grants$430%
  • Travel & lodging$2,2733%
  • Food & beverage$24,81636%
  • Education$3160%
  • Other$17,79226%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Penumbra, Inc.12$47,506
Angiodynamics, Inc.12$18,007
Pfizer57$11,828
Cardiovascular Systems Inc.27$3,667
Bayer6$2,993
Boston Scientific50$2,972
Siemens Medical Solutions USA, Inc.3$2,536
Abbott34$1,997
GSK67$1,641
Kestra Medical Technology Services, Inc.43$1,424
E.r. Squibb & Sons, L.L.C.85$1,147
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)40$1,030
Novo Nordisk44$892
Johnson & Johnson42$822
Cardinal Health 200 LLC45$737
Philips North America LLC60$681
Medtronic(2 entities)34$630
Imperative Care, Inc24$594
Amgen24$578
Merck44$572
Boehringer Ingelheim20$561
AstraZeneca26$554
Terumo Medical Corporation6$549
Endologix LLC26$493
Preventice Services, LLC16$457
Novartis26$452
Tactile Systems Technology Inc22$450
Lilly USA, LLC15$425
Alnylam Pharmaceuticals Inc.15$378
Abiomed3$271
Inquis Medical, Inc.2$270
United Therapeutics Corporation11$253
Actelion Pharmaceuticals US, Inc.5$251
Truvic Medical, Inc.4$232
Astellas Pharma US Inc2$199
Ablative Solutions, Inc.2$187
Biotronik Inc.2$172
Innova Vascular Inc.1$160
Bard Peripheral Vascular, Inc.4$151
Avinger Inc.1$130
Venclose Inc.2$126
Kiniksa Pharmaceuticals International, PLC3$124
Edwards Lifesciences1$118
Cordis US CORP.7$118
Amarin Pharma, Inc.7$105
American Regent1$102
Cvrx, Inc.7$100
Impulse Dynamics (USA) Inc.4$97
Baxter Healthcare1$91
Lexicon Pharmaceuticals, Inc.5$86
Sanofi-aventis U.S. LLC5$85
Bridgebio Pharma, Inc.3$74
Stryker1$60
Bardy Diagnostics, Inc.4$55
Heartflow, Inc.2$51
Biosense Webster, Inc.1$48
Cook Medical LLC3$43
Getinge USA Sales, LLC3$41
Regeneron Healthcare Solutions, Inc.2$40
Medicomp Inc2$36

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$110,744 in reported general payments places this provider in the 90th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$1,604,649
Medicare patients
853
Services billed
20,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide536$639,042
MounjaroTirzepatide530$568,656
EliquisApixaban590$512,668
EntrestoSacubitril/Valsartan440$428,944
JardianceEmpagliflozin281$262,662
XareltoRivaroxaban288$250,572
TrulicityDulaglutide167$188,884
BrilintaTicagrelor172$132,761
FarxigaDapagliflozin Propanediol151$131,138
Repatha SureclickEvolocumab118$79,244
Trelegy ElliptaFluticasone/Umeclidin/Vilanter96$69,432
MultaqDronedarone Hcl20$25,574
Ranolazine ErRanolazine268$21,467
Praluent PenAlirocumab34$16,687
WegovySemaglutide12$16,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$425$757,541697 claims
Novo NordiskOzempic, Wegovy$892$655,277548 claims
PfizerEliquis$11,828$512,668590 claims
NovartisEntresto$452$428,944440 claims
AstraZenecaBrilinta, Farxiga$554$263,899323 claims
Boehringer IngelheimJardiance$561$262,662281 claims
Johnson & JohnsonXarelto$822$250,572288 claims
GSKTrelegy Ellipta$1,641$69,43296 claims
Sanofi-aventis U.S. LLCMultaq$85$25,57420 claims
MerckVerquvo$572$11,20314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →